← Back
Data updated: Mar 29, 2026
SANKYO
OncologyCardiovascularGastroenterology
Specialty
SANKYO is a specialty pharmaceutical company focused on Oncology, Cardiovascular, Gastroenterology.
1992
Since
2
Drugs
-
Trials
0
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
No recent activity
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 69%
0 drugs Phase 3: 22 Phase 2: 22 Phase 1: 43
Cardiovascular 16%
0 drugs Phase 3: 9 Phase 2: 2 Phase 1: 2
Gastroenterology 8%
0 drugs Phase 3: 2 Phase 2: 3 Phase 1: 6
Respiratory 5%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 2
Metabolic 2%
0 drugs Phase 2: 3
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
Boehringer Ingelheim big-pharma
Metabolic, Oncology, Respiratory, Cardiovascular
BRACCO specialty
Cardiovascular, Oncology, Metabolic, Respiratory
Merck big-pharma
Oncology, Cardiovascular, Metabolic